VYGR Voyager Therapeutics Inc Total Business Assets

VYGR (Voyager Pharma) - company brandmark

Voyager Therapeutics (VYGR) focuses on developing genetic material transport systems for neurons to treat severe brain pathologies. This daily price chart for the company, which holds total assets of 259.90, confirms the financial foundation necessary to advance intellectual property protections and execute joint projects for dementia treatment. The company is currently implementing automated complexes where robotics accelerate the selection of the most effective viral vectors.

Cumulative Company Assets: Voyager Therapeutics (VYGR) for 07/04/2022 - 11/01/2026

Analytical breakdowns and data insights for company Voyager Pharma (VYGR)

- stock price and consensus target price:
Price Performance Chart voyagertherapeutics.com|VYGR - Price Target Chart
- market capitalization data:
Market Capitalization Voyager Corp|VYGR - Enterprise Value
- book capitalization information:
Net Asset Value per Share Voyager Therapeutics|VYGR - Company Net Assets|Market Capitalization to Book Value Ratio voyagertherapeutics.com|VYGR - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Voyager Therapeutics|VYGR - Long-Term Debt to Equity|Current Liabilities to Capital Voyager Corp|VYGR - Company Total Debt|Debt to Book Capitalization Ratio Voyager Corp|VYGR - Company Long-Term Debt|Short-Term Debt Voyager Therapeutics|Immediate Liquidity voyagertherapeutics.com
- company profitability and valuation multiples indicators:
VYGR - Net Profit
Summary company analysis:voyagertherapeutics.com, VYGR
Manufactured products of Voyager Therapeutics, Inc.

Total assets represent the aggregate value of all corporate resources, defining the scale of the company's financial base. This chart of gross assets reflects the current valuation of Voyager Therapeutics (VYGR) property at 259.90. This metric is calculated inversely via the ROA indicator, allowing for the real-time tracking of balance sheet changes. For Voyager Therapeutics (VYGR), the growth of this indicator confirms the effective capitalization of the Tracer platform's intellectual property and revenues from pharmaceutical licenses.

Main competitors

biogen.com - Aggregate Asset Value|Aggregate Company Assets Neurocrine Biosciences, Inc.|Total Business Assets RGC (Regencell Bioscience Ltd)|Company Total Assets AXSM|ACAD - Company Assets|Xenon Pharmaceuticals - Cumulative Company Assets|Company Total Assets vikingtherapeutics.com VKTX|SUPN - Aggregate Company Assets|Aggregate Asset Value CPRX (Catalyst Pharma)|Denali Therapeutics Inc (DNLI) - Aggregate Company Assets|Company Assets Harmony Corp (HRMY)|Cumulative Company Assets BHVN|Aggregate Company Assets AMLX|Aggregate Company Assets Trevi Therapeutics, Inc. (TRVI)|PRAX - Company Assets|Anavex Corp - Cumulative Company Assets|CeriBell EEG (CBLL) - Company Assets|Prothena Corporation plc - Company Total Assets|ALEC - Company Total Assets|ANNX: Company Total Assets|Company Balance Sheet Assets Omeros OMER|NGNE (Neurogene Corp) - Company Total Assets|Company Assets AC Immune Inc ACIU|Aggregate Company Assets Neumora Therapeutics (NMRA)|SCLX (scilexholding.com) - Aggregate Asset Value|Tevogen Bio - Cumulative Company Assets|Aggregate Asset Value ACOG|CGTX: Cumulative Company Assets|Inhibikase Pharma - Aggregate Business Assets|SAVA: Company Total Assets|Assertio - Aggregate Asset Value|COYA (Coya Therapeutics Inc) - Company Total Assets|Company Assets VistaGen Therapeutics Inc VTGN|Aggregate Company Assets Ovid Therapeutics Inc. (OVID)|ABOS (Acumen Pharmaceuticals, Inc) - Aggregate Asset Value|Company Total Assets CRVO (CervoMed Inc.)|Company Total Assets Alterity Therapeutics Ltd. ATHE|CLNN - Aggregate Company Assets|Total Asset Value of Company PEPG|JUNS: Company Total Assets|Company Assets Relmada Corp (RLMD)|Cumulative Company Assets ANVS|Company Total Assets Grace Tx|Cumulative Company Assets AIFF (Firefly Neuroscience)|Aggregate Business Assets KLTO|Company Total Assets NRSN (NeuroSense Therapeutics Ltd.)|Company Total Asset Base Reviva Pharmaceuticals, Inc. (RVPH)|MetaVia, Inc. - Company Total Assets|neuraxis.com (NRXS) - Cumulative Company Assets|heliusmedical.com (HSDT) - Aggregate Company Assets|PASG - Company Total Asset Base|Cumulative Company Assets NEUP|Aggregate Company Assets NERV|Cumulative Company Assets ATHA (Athira Pharma, Inc.)|ADXN - Company Assets|Company Total Assets ALZN (Alzamend Neuro)|Company Balance Sheet Assets Cyclerion Therapeutics Inc.|PTIX - Aggregate Company Assets|Aggregate Asset Value KTTA (Pasithea Therapeutics)|cortigent.com (CRGT) - Aggregate Company Assets|Total Business Assets ATXI|BCLI (BrainStorm Cell Therapeutics) - Company Total Assets|Company Assets Cara Therapeutics Inc. CARA|Cumulative Company Assets CHRO (Chromocell Therapeutics Corporation)|Company Total Assets eliemtx.com (ELYM)|Aggregate Company Assets Intra-Cellular Therapies, Inc. ITCI|Aggregate Asset Value LBPH|MRNS - Aggregate Company Assets|Company Assets NKGen Biotech Inc|NRBO (NeuroBo) - Cumulative Company Assets|SAGE (Sage Therapeutics Inc) - Aggregate Company Assets|Aggregate Company Assets Synaptogenix, Inc.|Company Assets trevena.com TRVN|Cumulative Company Assets VIGL (Vigil Neuroscience)|WENA - Company Assets|Company Total Assets CERE (Cerevel)